There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.
Shaji Kumar
Advertisement
Articles by Shaji Kumar
Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Shaji Kumar on Treatment-Related Adverse Events From Monoclonal AntibodiesSeptember 22nd 2015
Shaji Kumar on Later Lines of Treatment for MyelomaSeptember 22nd 2015
Advertisement
Advertisement
Trending on CURE
1
Why Cancer Survivorship Can Be the Hardest Part, Psychologist Says
2
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
3
Experimental Treatment Shrinks Tumors in Aggressive Adenoid Cystic Carcinoma
4
5-Year Data Support Personalized Vaccine in High-Risk Melanoma
5